BiotechTube

LCZ696 (sacubitril/valsartan)

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Hearth Failure With Reduced Ejection Fraction (HFrEF)

Conditions

Hearth Failure With Reduced Ejection Fraction (HFrEF)

Trial Timeline

Mar 8, 2016 → Nov 29, 2017

NCT ID
NCT02690974

About LCZ696 (sacubitril/valsartan)

LCZ696 (sacubitril/valsartan) is a approved stage product being developed by Novartis for Hearth Failure With Reduced Ejection Fraction (HFrEF). The current trial status is completed. This product is registered under clinical trial identifier NCT02690974. Target conditions include Hearth Failure With Reduced Ejection Fraction (HFrEF).

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT02887183ApprovedCompleted
NCT02690974ApprovedCompleted